Zai Lab shares are trading higher after the company received Breakthrough Therapy Designation for investigational repotrectinib in China.
Portfolio Pulse from Benzinga Newsdesk
Zai Lab has received Breakthrough Therapy Designation for its investigational repotrectinib in China, leading to a rise in its share prices.
August 30, 2023 | 4:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zai Lab's stock price is trading higher after receiving Breakthrough Therapy Designation for repotrectinib in China.
The Breakthrough Therapy Designation is a significant regulatory milestone that can expedite the development and review of drugs intended to treat serious conditions. This positive news has led to an increase in Zai Lab's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100